Nicely said! Was literally about to reply to @topfeeder with...

Nicely said! Was literally about to reply to @topfeeder with everything you've said.

Cohort 1 patients aren't going through efficacy testing. The test patients are generally late-stage and have had 2 prior therapies that didn't quite stack up. This means they are very high risk as far as their immunity is concerned. The low doage is literally ensuring Vaxinia isn't poisonous...that's it! To complain that Ph1, Cohort 1 trails aren't yielding any efficacy results is absurd. CHECKvacc was only cleared for "inital efficacy" testing in Ph1 for patients in cohort 3.

The recent patient tests across the board are yielding amazing low/zero toxity results, which is fundamentally shocking and what we first need to see before upping the ante, especially given the test patients health sensitivities.

To conclude, these announcements are very relevant and price-sensitive, and not, as @topfeeder puts it, "Hotcopper forum sensitive".

DYOR, like, actually do research before spouting nonsense. GLT...most...H...